After primary immunization with adsorbed DPT vaccine antitetanus immunity was retained for 9-10 years in 90.6-98.4% of children covered by this study. The second booster immunization of children against tetanus with adsorbed DT toxoid with reduced antigen content, made at an interval prolonged to 7-10 years under the conditions of lower antitoxic immunity, ensured a high level of intense antitetanus immunity. These data point to the possibility of prolonging the interval between booster immunizations to 9-10 years and reducing the number of injections and antigenic load.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
A Preliminary Study to Evaluate the Immune Response to a Booster Dose of the Adult Tetanus-Diphtheria Vaccine (Td) Available in Iran.
Iran J Pharm Res
September 2024
Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran.
Background: Despite the availability of tetanus-diphtheria (TD) vaccines in Iran, the seroconversion rate of these products as a booster dose is unknown.
Objectives: This study evaluates the seroconversion rate of the Iranian Td vaccine in adults who have not been vaccinated in the past decade.
Methods: In this study, 20 adult volunteers aged 18 to 60 who had not received the Td vaccine in the past decade received a booster dose of the Iranian Td vaccine.
Anti-Tetanus Vaccination Is Associated with Reduced Occurrence and Slower Progression of Parkinson's Disease-A Retrospective Study.
Biomedicines
November 2024
Brain Institute, Tel-Aviv Sourasky Medical Center, Faculty of Medical & Health Sciences, Sagol School of Neurosciences, Tel Aviv University, Tel-Aviv 6997801, Israel.
Parkinson's disease (PD) is a neurodegenerative disorder that progressively damages the autonomic and central nervous systems, leading to hallmark symptoms such as resting tremor, bradykinesia, and rigidity. Despite extensive research, the underlying cause of PD remains unclear, and current treatments are unable to halt the progression of the disease. In this retrospective study, based on historical electronic health records (EHR) from a national health provider covering the period from 2003 to 2023, we investigated the impact of vaccination and medication purchases on PD occurrence and severity.
View Article and Find Full Text PDFSeroprevalence of antibodies against diphtheria, tetanus, and pertussis across various age groups during the post-COVID-19 pandemic period in Chonburi Province, Thailand.
Heliyon
November 2024
Center of Excellence in Clinical Virology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand.
Background: Limited data exists regarding population immunity against diphtheria, tetanus, and pertussis in Thailand during the post-COVID-19 pandemic period. This study aimed to evaluate the age-specific seroprevalence of anti-diphtheria toxoid (anti-DT) IgG, anti-tetanus toxoid (anti-TT) IgG, and anti-pertussis toxin (anti-PT) IgG in individuals across diverse age groups in Chonburi province, Thailand following the COVID-19 pandemic.
Methods: Between October 2022 and January 2023, a total of 657 participants from Chonburi Province, Thailand, were included in this study.
Seroprevalence of IgG antibodies against tetanus toxoid among different age groups in Poland.
Ann Agric Environ Med
September 2024
National Institute of Public Health NIH - National Research Institute, Warsaw, Poland.
Article Synopsis
- The study aimed to assess the prevalence of tetanus antibodies in the population to gauge vaccine-induced immunity and identify groups needing booster shots.* -
- A total of 2,842 serum samples from individuals aged 1 month to 97 years were tested, revealing that 5.2% had low antibody levels and over half required immediate booster vaccinations.* -
- Results indicated that young adults showed the highest antibody levels and avidity, while older adults (70+) had significantly lower immunity, suggesting they are the main target for booster doses.*
Phase 1 trial of an investigational Tdap booster vaccine with CpG 1018 adjuvant compared with Boostrix in healthy adults and adolescents.
Vaccine
October 2024
Dynavax Technologies Corporation, Emeryville, CA, USA. Electronic address:
This phase 1 trial assessed the safety and immunogenicity of an investigational tetanus/diphtheria/acellular pertussis vaccine combined with CpG 1018 adjuvant 1500 μg (Tdap-1018 1500 μg) or 3000 μg (Tdap-1018 3000 μg) in adults and adolescents. In this randomized, active-controlled, multicenter, dose-escalation trial, healthy participants aged 10 to 22 years received 1 dose of Tdap-1018 1500 μg, Tdap-1018 3000 μg, or Boostrix. Geometric mean concentrations (GMCs) and booster response rates (BRRs) for antibodies against pertussis (pertussis toxin, filamentous hemagglutinin, pertactin), tetanus, and diphtheria antigens, and neutralizing antibodies against pertussis toxin were assessed 4 weeks after vaccination.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!